A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Study Overview

• Status: Terminated
• Conditions: Macular Degeneration; Retinal Degeneration; Geographic Atrophy; Dry Age-related Macular Degeneration; Retinal Disease
• Intervention / Treatment: Drug: GEM103

Detailed Description

This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.

• Study Type: Interventional
• Enrollment (Actual): 62
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85020
      • Gemini Clinical Trial Site
  • California
    • Bakersfield, California, United States, 93309
      • Gemini Clinical Trial Site
    • Beverly Hills, California, United States, 90211
      • Gemini Clinical Trial Site
    • Oxnard, California, United States, 93036
      • Gemini Clinical Trial Site
    • Poway, California, United States, 92064
      • Gemini Clinical Trial Site
    • Santa Barbara, California, United States, 93103
      • Gemini Clinical Trial Site
    • Santa Maria, California, United States, 93454
      • Gemini Clinical Trial Site
  • Colorado
    • Golden, Colorado, United States, 80401
      • Gemini Clinical Trial Site
  • Connecticut
    • New London, Connecticut, United States, 06320
      • Gemini Clinical Trial Site
  • Florida
    • Palm Beach Gardens, Florida, United States, 33410
      • Gemini Clinical Trial Site
    • Saint Petersburg, Florida, United States, 33711
      • Gemini Clinical Trial Site
    • Tallahassee, Florida, United States, 32308
      • Gemini Clinical Trial Site
    • Winter Haven, Florida, United States, 33880
      • Gemini Clinical Trial Site
  • Georgia
    • Augusta, Georgia, United States, 30909
      • Gemini Clinical Trial Site
    • Marietta, Georgia, United States, 30060
      • Gemini Clinical Trial Site
  • Illinois
    • Oak Park, Illinois, United States, 60304
      • Gemini Clinical Trial Site
  • Indiana
    • Indianapolis, Indiana, United States, 46290
      • Gemini Clinical Trial Site
  • Missouri
    • Chesterfield, Missouri, United States, 63017
      • Gemini Clinical Trial Site
    • Saint Louis, Missouri, United States, 63144
      • Gemini Clinical Trial Site
  • Nevada
    • Reno, Nevada, United States, 89502
      • Gemini Clinical Trial Site
  • New Jersey
    • Bloomfield, New Jersey, United States, 07003
      • Gemini Clinical Trial Site
  • North Carolina
    • Asheville, North Carolina, United States, 28803
      • Gemini Clinical Trial Site
    • Charlotte, North Carolina, United States, 28210
      • Gemini Clinical Trial Site
  • Oregon
    • Eugene, Oregon, United States, 97401
      • Gemini Clinical Trial Site
  • South Dakota
    • Rapid City, South Dakota, United States, 57701
      • Gemini Clinical Trial Site
  • Texas
    • Abilene, Texas, United States, 79606
      • Gemini Clinical Trial Site
    • Dallas, Texas, United States, 75231
      • Gemini Clinical Trial Site
    • The Woodlands, Texas, United States, 77384
      • Gemini Clinical Trial Site
  • Virginia
    • Virginia Beach, Virginia, United States, 23454
      • Gemini Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. At least 50 years old at the time of signed informed consent.

2. Must have one of the following genetic profiles:

   1. Genetic Profile A.
   2. Genetic Profile B.
3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).
4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.
5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.
6. Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.

Exclusion Criteria:

1. Presence of the following ocular conditions - in the study eye:

   1. Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.
   2. Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.
   3. Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.
   4. Aphakia or complete absence of the posterior capsule.
   5. History of laser therapy to the macula or fundus or extensive laser to the retina.
   6. Prior corneal transplant.

2. Presence of any of the following ocular conditions - in either eye:

   1. History of herpetic infection.
   2. Concurrent disease that could require medical or surgical intervention during the study period.
   3. Active uveitis and/or vitritis (grade: trace or above).
   4. History of idiopathic or autoimmune-associated uveitis.
   5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.
   6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.
3. In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.
4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.
5. Current use of medications known to be toxic to the lens, retina, or optic nerve.
6. Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort with Genetic Profile A; Subjects will have Genetic Profile A. Intervention: Biological: GEM103.	Drug: GEM103; Biological
Experimental: Cohort with Genetic Profile B; Subjects will have Genetic Profile B. Intervention: Biological: GEM103	Drug: GEM103; Biological

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.	18 months

Secondary Outcome Measures

Outcome Measure	Time Frame
To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale.	6 months
To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible.	6 months

Collaborators and Investigators

• Sponsor: Gemini Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 30, 2020
• Primary Completion (Actual): February 18, 2022
• Study Completion (Actual): March 21, 2022

Study Registration Dates

• First Submitted: November 16, 2020
• First Submitted That Met QC Criteria: November 19, 2020
• First Posted (Actual): November 25, 2020

Study Record Updates

• Last Update Posted (Actual): September 23, 2022
• Last Update Submitted That Met QC Criteria: September 22, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Pathological Conditions, Anatomical; Eye Diseases, Hereditary; Macular Degeneration; Retinal Diseases; Geographic Atrophy; Atrophy; Retinal Degeneration
• Other Study ID Numbers: GEM-CL-10302; REGATTA (Other Identifier: Gemini Therapeutics)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No